Literature DB >> 14639602

p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.

David Pim1, Lawrence Banks.   

Abstract

Two common polymorphic forms of the p53 tumor suppressor protein are widely distributed throughout the human population. These encode either proline or arginine at position 72, and this difference results in a marked alteration in the primary structure of the protein. A number of previous studies have shown significant differences in the biochemical properties of the p53 protein, depending on the particular polymorphic form. There is little information, however, on their respective biologic activities. In this study, we have used an inducible switch system for expressing both polymorphic forms of p53 within Saos-2 cells. Cell cycle analysis postinduction of p53 function reveals striking differences in how the 2 forms of p53 bring about a cessation of cell growth. Thus, the Arg72 form of p53 is significantly more efficient than the Pro72 form at inducing apoptosis. In contrast, the Pro72 form appears to induce a higher level of G1 arrest than the Arg72 form. These results demonstrate significant differences in how the codon 72 polymorphism affects the biological activity of p53. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14639602     DOI: 10.1002/ijc.11548

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  124 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  The role of p53 gene family in reproduction.

Authors:  Wenwei Hu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.

Authors:  Woon-Puay Koh; David Van Den Berg; Aizhen Jin; Renwei Wang; Jian-Min Yuan; Mimi C Yu
Journal:  Breast Cancer Res Treat       Date:  2011-07-21       Impact factor: 4.872

Review 4.  Genome maintenance and human longevity.

Authors:  Miook Cho; Yousin Suh
Journal:  Curr Opin Genet Dev       Date:  2014-08-28       Impact factor: 5.578

5.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

6.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

7.  Negative effect of P72 polymorphism on p53 gene in IVF outcome in patients with repeated implantation failure and pregnancy loss.

Authors:  Belén Lledo; Azahara Turienzo; Jose A Ortiz; Ruth Morales; Jorge Ten; Joaquin Llácer; Rafael Bernabeu
Journal:  J Assist Reprod Genet       Date:  2013-12-11       Impact factor: 3.412

8.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

9.  A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  Cancer Causes Control       Date:  2008-09-24       Impact factor: 2.506

10.  Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Authors:  Joanna Szkandera; Gudrun Absenger; Nadia Dandachi; Peter Regitnig; Sigurd Lax; Michael Stotz; Hellmut Samonigg; Wilfried Renner; Armin Gerger
Journal:  Mol Genet Genomics       Date:  2012-08-18       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.